Mersana Therapeutics, Inc. (NASDAQ:MRSN) Director Andrew A. F. Hack bought 250,000 shares of Mersana Therapeutics stock in a transaction on Tuesday, January 12th. The stock was purchased at an average price of $18.36 per share, for a total transaction of $4,590,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of MRSN stock opened at $19.12 on Thursday. The firm has a market cap of $1.31 billion, a P/E ratio of -14.16 and a beta of 2.56. Mersana Therapeutics, Inc. has a 1-year low of $4.12 and a 1-year high of $29.09. The company has a debt-to-equity ratio of 0.02, a current ratio of 13.05 and a quick ratio of 13.05. The firm’s 50-day simple moving average is $24.15 and its 200-day simple moving average is $21.16.

Mersana Therapeutics (NASDAQ:MRSN) last announced its quarterly earnings data on Monday, November 9th. The company reported ($0.33) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.02). Mersana Therapeutics had a negative return on equity of 45.16% and a negative net margin of 8,772.91%. The company had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.43 million. Analysts expect that Mersana Therapeutics, Inc. will post -1.33 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of MRSN. Great West Life Assurance Co. Can purchased a new position in Mersana Therapeutics in the second quarter valued at approximately $84,000. Point72 Hong Kong Ltd purchased a new position in Mersana Therapeutics in the second quarter valued at approximately $139,000. Marshall Wace LLP purchased a new position in Mersana Therapeutics in the first quarter valued at approximately $141,000. Bellecapital International Ltd. purchased a new position in Mersana Therapeutics in the third quarter valued at approximately $217,000. Finally, Truist Financial Corp purchased a new position in Mersana Therapeutics in the third quarter valued at approximately $218,000. Hedge funds and other institutional investors own 90.28% of the company’s stock.

A number of research analysts have issued reports on the stock. Stifel Nicolaus assumed coverage on shares of Mersana Therapeutics in a report on Wednesday, December 2nd. They issued a “buy” rating and a $33.00 target price on the stock. BidaskClub upgraded shares of Mersana Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Friday, December 18th. JPMorgan Chase & Co. initiated coverage on shares of Mersana Therapeutics in a report on Tuesday, September 29th. They issued a “neutral” rating on the stock. SVB Leerink increased their price objective on shares of Mersana Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a report on Monday, November 9th. Finally, Zacks Investment Research lowered shares of Mersana Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 9th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $26.83.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies.

See Also: What moving averages are used to define a golden cross?

Insider Buying and Selling by Quarter for Mersana Therapeutics (NASDAQ:MRSN)

Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.